Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.85
EBS's Cash to Debt is ranked lower than
81% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. EBS: 0.85 )
Ranked among companies with meaningful Cash to Debt only.
EBS' s 10-Year Cash to Debt Range
Min: 0.52  Med: 2.18 Max: N/A
Current: 0.85
Equity to Asset 0.60
EBS's Equity to Asset is ranked lower than
60% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. EBS: 0.60 )
Ranked among companies with meaningful Equity to Asset only.
EBS' s 10-Year Equity to Asset Range
Min: 0.33  Med: 0.70 Max: 0.81
Current: 0.6
0.33
0.81
Interest Coverage 7.05
EBS's Interest Coverage is ranked lower than
92% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. EBS: 7.05 )
Ranked among companies with meaningful Interest Coverage only.
EBS' s 10-Year Interest Coverage Range
Min: 7.05  Med: 274.92 Max: 9999.99
Current: 7.05
7.05
9999.99
F-Score: 7
Z-Score: 3.73
M-Score: -2.39
WACC vs ROIC
8.11%
8.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 14.46
EBS's Operating margin (%) is ranked higher than
83% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. EBS: 14.46 )
Ranked among companies with meaningful Operating margin (%) only.
EBS' s 10-Year Operating margin (%) Range
Min: -0.8  Med: 16.76 Max: 48.09
Current: 14.46
-0.8
48.09
Net-margin (%) 9.36
EBS's Net-margin (%) is ranked higher than
78% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. EBS: 9.36 )
Ranked among companies with meaningful Net-margin (%) only.
EBS' s 10-Year Net-margin (%) Range
Min: -1.22  Med: 11.83 Max: 46.34
Current: 9.36
-1.22
46.34
ROE (%) 8.39
EBS's ROE (%) is ranked higher than
82% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. EBS: 8.39 )
Ranked among companies with meaningful ROE (%) only.
EBS' s 10-Year ROE (%) Range
Min: 5.5  Med: 14.48 Max: 214.39
Current: 8.39
5.5
214.39
ROA (%) 4.93
EBS's ROA (%) is ranked higher than
82% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. EBS: 4.93 )
Ranked among companies with meaningful ROA (%) only.
EBS' s 10-Year ROA (%) Range
Min: 4.23  Med: 9.80 Max: 150.96
Current: 4.93
4.23
150.96
ROC (Joel Greenblatt) (%) 17.36
EBS's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. EBS: 17.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EBS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 11.5  Med: 24.33 Max: 116.14
Current: 17.36
11.5
116.14
Revenue Growth (3Y)(%) 9.20
EBS's Revenue Growth (3Y)(%) is ranked higher than
63% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. EBS: 9.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
EBS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -1.1  Med: 9.20 Max: 31.4
Current: 9.2
-1.1
31.4
EBITDA Growth (3Y)(%) 21.60
EBS's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. EBS: 21.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
EBS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -4.15 Max: 21.6
Current: 21.6
0
21.6
EPS Growth (3Y)(%) 7.70
EBS's EPS Growth (3Y)(%) is ranked higher than
65% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. EBS: 7.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
EBS' s 10-Year EPS Growth (3Y)(%) Range
Min: -26.7  Med: 0.80 Max: 61.7
Current: 7.7
-26.7
61.7
» EBS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

EBS Guru Trades in Q3 2014

Ken Fisher 483,328 sh (+3.11%)
Joel Greenblatt Sold Out
Jim Simons 539,411 sh (-11.21%)
Paul Tudor Jones 24,000 sh (-18.37%)
» More
Q4 2014

EBS Guru Trades in Q4 2014

Ken Fisher 501,428 sh (+3.74%)
Jim Simons 511,111 sh (-5.25%)
Paul Tudor Jones 7,500 sh (-68.75%)
» More
Q1 2015

EBS Guru Trades in Q1 2015

Paul Tudor Jones 12,692 sh (+69.23%)
Jim Simons 586,811 sh (+14.81%)
Ken Fisher 501,428 sh (unchged)
» More
Q2 2015

EBS Guru Trades in Q2 2015

Paul Tudor Jones 15,300 sh (+20.55%)
Jim Simons 671,511 sh (+14.43%)
Ken Fisher 462,428 sh (-7.78%)
» More
» Details

Insider Trades

Latest Guru Trades with EBS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 48.86
EBS's P/E(ttm) is ranked lower than
65% of the 220 Companies
in the Global Biotechnology industry.

( Industry Median: 33.70 vs. EBS: 48.86 )
Ranked among companies with meaningful P/E(ttm) only.
EBS' s 10-Year P/E(ttm) Range
Min: 6.72  Med: 21.19 Max: 71.97
Current: 48.86
6.72
71.97
Forward P/E 26.11
EBS's Forward P/E is ranked lower than
57% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. EBS: 26.11 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 55.00
EBS's PE(NRI) is ranked lower than
68% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 33.30 vs. EBS: 55.00 )
Ranked among companies with meaningful PE(NRI) only.
EBS' s 10-Year PE(NRI) Range
Min: 6.69  Med: 21.10 Max: 71.14
Current: 55
6.69
71.14
P/B 2.30
EBS's P/B is ranked higher than
72% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. EBS: 2.30 )
Ranked among companies with meaningful P/B only.
EBS' s 10-Year P/B Range
Min: 0.84  Med: 1.83 Max: 3.82
Current: 2.3
0.84
3.82
P/S 3.20
EBS's P/S is ranked higher than
78% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. EBS: 3.20 )
Ranked among companies with meaningful P/S only.
EBS' s 10-Year P/S Range
Min: 0.81  Med: 2.23 Max: 4.34
Current: 3.2
0.81
4.34
POCF 43.25
EBS's POCF is ranked lower than
61% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.50 vs. EBS: 43.25 )
Ranked among companies with meaningful POCF only.
EBS' s 10-Year POCF Range
Min: 2.96  Med: 13.87 Max: 106.04
Current: 43.25
2.96
106.04
EV-to-EBIT 18.91
EBS's EV-to-EBIT is ranked higher than
65% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 26.88 vs. EBS: 18.91 )
Ranked among companies with meaningful EV-to-EBIT only.
EBS' s 10-Year EV-to-EBIT Range
Min: 3.3  Med: 13.40 Max: 43.5
Current: 18.91
3.3
43.5
PEG 32.35
EBS's PEG is ranked lower than
92% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 2.22 vs. EBS: 32.35 )
Ranked among companies with meaningful PEG only.
EBS' s 10-Year PEG Range
Min: 8.43  Med: 18.27 Max: 66.15
Current: 32.35
8.43
66.15
Shiller P/E 46.45
EBS's Shiller P/E is ranked lower than
55% of the 112 Companies
in the Global Biotechnology industry.

( Industry Median: 44.71 vs. EBS: 46.45 )
Ranked among companies with meaningful Shiller P/E only.
EBS' s 10-Year Shiller P/E Range
Min: 13.16  Med: 21.31 Max: 48.79
Current: 46.45
13.16
48.79
Current Ratio 5.01
EBS's Current Ratio is ranked higher than
56% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. EBS: 5.01 )
Ranked among companies with meaningful Current Ratio only.
EBS' s 10-Year Current Ratio Range
Min: 1.22  Med: 3.49 Max: 5.57
Current: 5.01
1.22
5.57
Quick Ratio 4.03
EBS's Quick Ratio is ranked higher than
51% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. EBS: 4.03 )
Ranked among companies with meaningful Quick Ratio only.
EBS' s 10-Year Quick Ratio Range
Min: 0.76  Med: 3.24 Max: 5.17
Current: 4.03
0.76
5.17
Days Inventory 237.63
EBS's Days Inventory is ranked lower than
79% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. EBS: 237.63 )
Ranked among companies with meaningful Days Inventory only.
EBS' s 10-Year Days Inventory Range
Min: 80.35  Med: 123.79 Max: 311.38
Current: 237.63
80.35
311.38
Days Sales Outstanding 76.52
EBS's Days Sales Outstanding is ranked lower than
59% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. EBS: 76.52 )
Ranked among companies with meaningful Days Sales Outstanding only.
EBS' s 10-Year Days Sales Outstanding Range
Min: 7.07  Med: 53.40 Max: 124.36
Current: 76.52
7.07
124.36

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 23.78
EBS's Price/Net Current Asset Value is ranked lower than
87% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. EBS: 23.78 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EBS' s 10-Year Price/Net Current Asset Value Range
Min: 3.59  Med: 5.95 Max: 42.93
Current: 23.78
3.59
42.93
Price/Tangible Book 3.26
EBS's Price/Tangible Book is ranked higher than
65% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. EBS: 3.26 )
Ranked among companies with meaningful Price/Tangible Book only.
EBS' s 10-Year Price/Tangible Book Range
Min: 0.88  Med: 1.96 Max: 3.92
Current: 3.26
0.88
3.92
Price/Projected FCF 2.86
EBS's Price/Projected FCF is ranked higher than
65% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. EBS: 2.86 )
Ranked among companies with meaningful Price/Projected FCF only.
EBS' s 10-Year Price/Projected FCF Range
Min: 1.12  Med: 1.77 Max: 2.83
Current: 2.86
1.12
2.83
Price/DCF (Earnings Based) 6.24
EBS's Price/DCF (Earnings Based) is ranked lower than
93% of the 14 Companies
in the Global Biotechnology industry.

( Industry Median: 1.18 vs. EBS: 6.24 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.58
EBS's Price/Median PS Value is ranked lower than
71% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. EBS: 1.58 )
Ranked among companies with meaningful Price/Median PS Value only.
EBS' s 10-Year Price/Median PS Value Range
Min: 0.38  Med: 0.93 Max: 1.99
Current: 1.58
0.38
1.99
Price/Graham Number 2.05
EBS's Price/Graham Number is ranked higher than
68% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 3.26 vs. EBS: 2.05 )
Ranked among companies with meaningful Price/Graham Number only.
EBS' s 10-Year Price/Graham Number Range
Min: 0.51  Med: 1.35 Max: 2.68
Current: 2.05
0.51
2.68
Earnings Yield (Greenblatt) (%) 5.27
EBS's Earnings Yield (Greenblatt) (%) is ranked higher than
90% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. EBS: 5.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EBS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 2.3  Med: 7.50 Max: 30.2
Current: 5.27
2.3
30.2
Forward Rate of Return (Yacktman) (%) 3.55
EBS's Forward Rate of Return (Yacktman) (%) is ranked lower than
68% of the 103 Companies
in the Global Biotechnology industry.

( Industry Median: 13.70 vs. EBS: 3.55 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
EBS' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -12.2  Med: -0.50 Max: 9.1
Current: 3.55
-12.2
9.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ER4.Germany,
Emergent BioSolutions Inc was incorporated as BioPort Corporation under the laws of Michigan in May 1998 and subsequently reorganized as a Delaware corporation in June 2004. The Company is a biopharmaceutical company, which is focused on the development, manufacture and commercialization of vaccine and immune-related therapeutic that assist the body's immune system to prevent or treat disease. It develops vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism and biowarfare and infectious diseases that have resulted in significant unmet or underserved public health needs. The Company manufactures and markets BioThrax(r), also referred to as anthrax vaccine adsorbed, the only vaccine approved by the U.S. Food and Drug Administration, or FDA, for the prevention of anthrax infection. BioThrax is approved for pre-exposure prevention of anthrax infection by all routes of exposure, including inhalation. The Company operates in two business segments, biodefense and biosciences. Its biodefense segment focuses on vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism or biowarfare. Its product candidates in this segment are focused on two specific biological agents: anthrax and botulinum. Within its anthrax product portfolio, the Company manufactures and markets BioThrax(r) (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. In addition to BioThrax, the Company is developing a recombinant protective antigen anthrax, or rPA, vaccine an advanced BioThrax vaccine, an anthrax immune globulin therapeutic and a recombinant anthrax monoclonal antibody therapeutic. Within its botulinum product portfolio, it is developing a recombinant botulinum vaccine. The Company's Biosciences division is a specialty pharmaceutical business focused on therapeutics and vaccines in hematology/oncology, transplantation and infectious disease. The Company's products and any product or product candidate that it acquires or successfully develop and commercialize is likely to compete with currently marketed products, such as vaccines, antibody therapies, antibiotics and other product candidates that are in development for the same indications. Specifically, the competition for its products and product candidates includes BioThrax, RSDL, BAT, AIGIV, VIGIV and PreviThrax and NuThrax. Accordingly, it is subject to federal, state, local and foreign laws and regulations governing the use, manufacture, distribution, storage, handling, disposal and recordkeeping of these materials.
» More Articles for EBS

Headlines

Articles On GuruFocus.com
Emergent BioSolutions Inc. Reports Operating Results (10-Q) Nov 05 2010 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) Aug 06 2010 
Emergent BioSolutions Inc. (EBS) President & COO Daniel Abdun-nabi sells 18,150 Shares Jul 30 2010 
Weekly CEO Sells Highlight: Yum! Brands Inc, Marchex Inc, iGate Corp, and Emergent BioSolutions Inc. Jul 25 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 18,800 Shares Jul 23 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 130,100 Shares Jul 22 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 84,433 Shares Jul 19 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 52,000 Shares May 14 2010 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) May 06 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 25,000 Shares Apr 29 2010 

More From Other Websites
Emergent BioSolutions, Inc. Earnings Q2, 2015 Sep 01 2015
31.08.2015 - Sergiu Manea to become CEO of BCR, starting with October 1st 2015 Aug 31 2015
26.08.2015 - Erste Bank opens new service branch office at Auhof Center Aug 27 2015
25.08.2015 - Pavel Kysilka decides to leave Česká Spořitelna at the end of 2015. His position... Aug 25 2015
Emergent BioSolutions competitor gets $143M federal contract for anthrax vaccine work Aug 20 2015
Emergent BioSolutions Gets $44M CDC Contract for VIGIV Aug 14 2015
Emergent BioSolutions Receives $44 Million CDC Contract to Further Advance Vaccinia Immune Globulin... Aug 13 2015
Emergent BioSolutions Receives $44 Million CDC Contract to Further Advance Vaccinia Immune Globulin... Aug 13 2015
10-Q for Emergent BioSolutions, Inc. Aug 09 2015
Emergent BioSolutions Tops on Q2 Earnings, Plans Spin-Off - Analyst Blog Aug 07 2015
07.08.2015 - Erste Group posts net profit of EUR 487.2 million in H1 15; Aug 07 2015
07.08.2015 - Erste Group posts net profit of EUR 487.2 million in H1 15; NPL ratio improves to 7.7%,... Aug 07 2015
Edited Transcript of EBS earnings conference call or presentation 6-Aug-15 12:00pm GMT Aug 06 2015
Why spin out a new bio company? When your cancer work isn't getting the attention it deserves. Aug 06 2015
Emergent BioSolutions Proposed Spin-off of BioSciences Business & Q2 2015 Earnings Call scheduled... Aug 06 2015
Emergent BioSolutions Reports Second Quarter and Six Months 2015 Financial Results and Reaffirms... Aug 06 2015
Emergent BioSolutions Announces Plan to Implement Tax-Free Spin-Off of Biosciences Business Into a... Aug 06 2015
Emergent Biosolutions posts 2Q profit Aug 06 2015
Emergent Biosolutions posts 2Q profit Aug 06 2015
EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK